EP08.02-139 A Phase 2 Study of Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIs

Lu, S.; Zhang, G.; Zhou, J.; Cang, S.; Cheng, Y.; Wu, G.; Cao, P.; Lv, D.; Jian, H.; Chen, C.; Jin, X.; Tian, P.; Wang, K.; Jiang, G.; Chen, G.; Chen, Q.; Zhao, H.; Ding, C.; Guo, R.; Sun, G.; Wang, B.; Jiang, L.; Liu, Z.; Fang, J.; Yang, J.; Zhuang, W.; Liu, Y.; Zhang, J.; Pan, Y.; Chen, J.; Yu, Q.; Zhao, M.; Cui, J.; Li, D.; Yi, T.; Yu, Z.; Yang, Y.; Zhang, Y.; Zhi, X.; Huang, Y.; Wu, R.; Chen, L.; Zang, A.; Cao, L.; Li, Q.; Li, X.; Song, Y.; Wang, D.; Zhang, S.

doi:10.1016/j.jtho.2022.07.822

Journal of Thoracic Oncology

2022

DOI: 10.1016/j.jtho.2022.07.822

|View full text |Cite

EP08.02-139 A Phase 2 Study of Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIs

S. Lu¹,

G. Zhang²,

J. Zhou³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

The advance of the third‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer (Review)

Cheng,

Cui,

Wang

et al. 2023

Oncol Rep

View full text Add to dashboard Cite

Lung cancer is currently the second most common type of cancer with the second incidence rate and the first mortality rate worldwide. Non-small cell lung cancer (NSCLC) accounts for ~85% of the total number of cases of lung cancers. Concerning the treatment of NSCLC, targeted therapy has become a research hotspot in recent years because of its favorable efficacy, high selectivity and minimal adverse reactions. Among the drugs used in targeted therapy, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the most common and are categorized into four generations. The use of first and second-generation drugs leads to drug resistance within 8-14 months. This resistance is primarily caused by the T790M mutation, which is the most observed mechanism. A third-generation drug has been developed to address this issue and a fourth-generation drug is expected to overcome multiple resistance mechanisms, including third-generation drug resistance. However, the fourth-generation drug has not been launched yet. At present, multiple third-generation targeted drugs have been launched globally, with three being launched in China and several being at research and clinical trial stages. The present article provides a review of the development process, mechanism of action and clinical trials of the third-generation EGFR-TKIs, aiming to provide some reference and suggestions for the clinical treatment of NSCLC and scientific research on third-generation targeted drugs. Contents 1. Introduction 2. History of the EGFR-targeted drugs 3. Mechanism 4. Third-generation EGFR-TKIs 5. Comparison of drug efficacy and clinical plan recommendations 6. Advantages and disadvantages of the third-generation EGFR TKIs 7. Prospects

show abstract

The advance of the third‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer (Review)

Cheng,

Cui,

Wang

et al. 2023

Oncol Rep

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

EP08.02-139 A Phase 2 Study of Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIs

Cited by 1 publication

References 0 publications

The advance of the third‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer (Review)

The advance of the third‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer (Review)

Contact Info

Product

Resources

About